THQ struggles with healthcare sector underperformance and trades at a premium. Read the full report on why THQ's high yield ...

DRI Healthcare Trust terminated management agreement with DRI Capital in exchange for $48M, plus accrued management and ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

Athletics New Zealand is delighted to announce the addition of the short track championships, set to debut at the Mitre 10 ...

Debt-to-equity ratios vary by company and industry, but in general, a ratio of 1.0 or less is considered rather safe. One of ...

The Department of Internal Affairs, Te Tari Taiwhenua, has released the most popular Māori baby names for 2024/2025. For the third consecutive year, Aroha/Te Aroha/Te-Aroha/TeAroha (173) topped the ...

Merck’s first quarter results drew a positive market reaction, reflecting operational resilience despite a 1.6% ...

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.

Only a few days prior, Sanofi also stated that it would simplify its R&D structure, but noted only that an undisclosed number of staff would leave.

Pharma Merck's Keytruda wins breakthrough head and neck cancer nod around surgery, but with a limitation By Angus Liu Jun 13, 2025 10:50am Merck & Co. Keytruda head and neck cancer PD-1/L1 ...

Merck is also working on different strategies to drive Keytruda's long-term growth. These include innovative immuno-oncology combinations, including Keytruda with LAG3 and CTLA-4 inhibitors.

Nonetheless, though Keytruda will lose patent exclusivity in 2028, its sales are expected to remain strong until then. Merck is also working on different strategies to drive Keytruda's long-term ...